Acadia Pharmaceuticals Inc Sample Contracts

Acadia Pharmaceuticals Inc – ONE PASEO OFFICE LEASE (February 27th, 2019)

This Office Lease (this "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between KILROY REALTY, L.P., a Delaware limited partnership ("Landlord"), and ACADIA PHARMACEUTICALS INC., a Delaware corporation ("Tenant").

Acadia Pharmaceuticals Inc – FORM OF AMENDED AND RESTATED WARRANT (February 27th, 2019)

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS OR UNLESS OFFERED, SOLD, PLEDGED, HYPOTHECATED OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS. THE COMPANY SHALL BE ENTITLED TO REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED TO THE EXTENT THAT AN OPINION IS REQUIRED PURSUANT TO THE AGREEMENT UNDER WHICH THE SECURITIES WERE ISSUED.

Acadia Pharmaceuticals Inc – 16,176,471 Shares ACADIA PHARMACEUTICALS INC. UNDERWRITING AGREEMENT (November 28th, 2018)
Acadia Pharmaceuticals Inc – June 28, 2018 (November 6th, 2018)
Acadia Pharmaceuticals Inc – -Second Quarter Net Sales Grew to $57.1 Million, Representing a 17% Sequential Increase Over 1Q18 and 87% Increase Over 2Q17 -Announced FDA Approval of New Dosing Formulation and Strength of NUPLAZID® (Pimavanserin) -Expanded ACADIA’s Pipeline in Central Nervous System Disorders with Exclusive License Agreement for the North American Development and Commercialization of Trofinetide (August 8th, 2018)

Announced an exclusive license agreement with Neuren Pharmaceuticals (ASX: NEU) for the North American development and commercialization of trofinetide for all indications, including Rett syndrome, a rare neurodevelopmental CNS disorder.  Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Acadia Pharmaceuticals Inc – LEASE AND LEASE AGREEMENT Between Boston Properties Limited Partnership The Landlord And ACADIA PHARMACEUTICALS INC. The Tenant For Leased Premises In 502 Carnegie Center Princeton, New Jersey May 15, 2018 (August 8th, 2018)

LEASE AND LEASE AGREEMENT, dated as of May 15, 2018, between Boston Properties Limited Partnership, a Delaware limited partnership with offices c/o Boston Properties at 101 Carnegie Center, Suite 104, Princeton, New Jersey 08540 (the "Landlord"), and ACADIA Pharmaceuticals Inc., a Delaware corporation, with its principal office at 3611 Valley Centre Drive, Suite 300, San Diego, California 92130 (the "Tenant").

Acadia Pharmaceuticals Inc – ACADIA PHARMACEUTICALS INC. 2010 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 12, 2010 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2010 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2013 APPROVED BY THE STOCKHOLDERS: JUNE 7, 2013 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2015 APPROVED BY THE STOCKHOLDERS: JUNE 15, 2015 AMENDED BY THE BOARD OF DIRECTORS: APRIL 29, 2016 APPROVED BY THE STOCKHOLDERS: JUNE 10, 2016 AMENDED BY THE BOARD OF DIRECTORS: APRIL 19, 2017 APPROVED BY THE STOCKHOLDERS: JUNE 13, 2017 AMENDED BY THE BOARD OF DIRECTORS: APRIL 30, 2018 APPROVED BY THE STOCKHOLDE (June 8th, 2018)
Acadia Pharmaceuticals Inc – Third Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc. (February 27th, 2018)

This Third Amendment to Product Agreement (this “Amendment”), dated December 11, 2017 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).

Acadia Pharmaceuticals Inc – COMMERCIAL SUPPLY AGREEMENT (February 27th, 2018)

This Commercial Supply Agreement is made as of this 22nd day of February, 2018 (the “Effective Date”), by and between ACADIA Pharmaceuticals Inc., a Delaware corporation, with a place of business at 3611 Valley Centre Drive, Suite 300, San Diego, California 92130 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (“Catalent”).

Acadia Pharmaceuticals Inc – ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results (November 7th, 2017)

SAN DIEGO, CA, November 7, 2017 – ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its unaudited financial results for the third quarter ended September 30, 2017.

Acadia Pharmaceuticals Inc – MSA Attachment No.4 (August 8th, 2017)

This MSA Attachment No.4 (MSA Attachment No.4) is entered into among Siegfried Evionnaz SA, route du Simplon 1, 1902 Evionnaz, Switzerland (Siegfried Evionnaz) and Siegfried AG, Untere Bruehlstrasse 4, 4800 Zofingen, Switzerland (Siegfried Zofingen and collectively with Siegfried Evionnaz, Siegfried) and ACADIA pharmaceuticals GmbH, c/o KENDRIS AG, Seidenhofstrasse 14, 6003 Luzern, Switzerland (ACADIA) under the Master Services Agreement dated December 15, 2016 (the Agreement). Pursuant to the Agreement, Siegfried has agreed to perform certain Services in accordance with written MSA Attachments, such as this one, entered into from time to time. Capitalized terms used in this MSA Attachment No. 4 and not otherwise defined have the meanings given to them in the Agreement.

Acadia Pharmaceuticals Inc – ACADIA PHARMACEUTICALS INC. 2010 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 12, 2010 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2010 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2013 APPROVED BY THE STOCKHOLDERS: JUNE 7, 2013 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2015 APPROVED BY THE STOCKHOLDERS: JUNE 15, 2015 AMENDED BY THE BOARD OF DIRECTORS: APRIL 29, 2016 APPROVED BY THE STOCKHOLDERS: JUNE 10, 2016 AMENDED BY THE BOARD OF DIRECTORS: APRIL 19, 2017 APPROVED BY THE STOCKHOLDERS: JUNE 13, 2017 (June 15th, 2017)
Acadia Pharmaceuticals Inc – February 24, 2017 Michael Yang (May 9th, 2017)
Acadia Pharmaceuticals Inc – ACADIA Pharmaceuticals Inc. 2004 Employee Stock Purchase Plan Offering (February 28th, 2017)

In this document, capitalized terms not otherwise defined shall have the same definitions of such terms as in the ACADIA Pharmaceuticals Inc. 2004 Employee Stock Purchase Plan.

Acadia Pharmaceuticals Inc – Master Services Agreement (February 28th, 2017)

ACADIA (and its Affiliates) engages in the business of research, development and commercialization of pharmaceutical compounds and products;

Acadia Pharmaceuticals Inc – CHANGE ORDER # 1 to MSA Attachment No. 1 (February 28th, 2017)

This Change Order #1 to MSA Attachment No. 1 (“Change Order”), is effective as of January 3, 2017, and amends certain provisions of the MSA Attachment No. 1 effective December 15, 2016 (the “Original MSA Attachment” and collectively with this Change Order, the “MSA Attachment”), between ACADIA Pharmaceuticals GmbH (“ACADIA”) and Siegfried AG (“SIEGFRIED”). The MSA Attachment is governed by the Master Services Agreement dated December 15, 2016 between ACADIA and SIEGFRIED.

Acadia Pharmaceuticals Inc – Second Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc. (November 7th, 2016)

This Second Amendment to Product Agreement (the “Amendment”), dated October 6, 2016 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).

Acadia Pharmaceuticals Inc – July 25, 2016 Todd Young (November 7th, 2016)
Acadia Pharmaceuticals Inc – 6,060,606 Shares ACADIA PHARMACEUTICALS INC. UNDERWRITING AGREEMENT (August 10th, 2016)
Acadia Pharmaceuticals Inc – First Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc. (August 4th, 2016)

This First Amendment to Product Agreement (the “Amendment”), dated April 25, 2016 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).

Acadia Pharmaceuticals Inc – ACADIA PHARMACEUTICALS INC. 2010 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 12, 2010 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2010 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2013 APPROVED BY THE STOCKHOLDERS: JUNE 7, 2013 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2015 APPROVED BY THE STOCKHOLDERS: JUNE 15, 2015 AMENDED BY THE BOARD OF DIRECTORS: APRIL 29, 2016 APPROVED BY THE STOCKHOLDERS: JUNE 10, 2016 (June 10th, 2016)
Acadia Pharmaceuticals Inc – ACADIA PHARMACEUTICALS INC. 2004 EMPLOYEE STOCK PURCHASE PLAN (June 10th, 2016)
Acadia Pharmaceuticals Inc – Contact: ACADIA Pharmaceuticals Inc. Lisa Barthelemy, Senior Director, Investor Relations (February 29th, 2016)
Acadia Pharmaceuticals Inc – ACADIA PHARMACEUTICALS INC. NONSTATUTORY STOCK OPTION GRANT NOTICE (2010 EQUITY INCENTIVE PLAN) (February 29th, 2016)

ACADIA PHARMACEUTICALS INC. (the “Company”), pursuant to its 2010 Equity Incentive Plan, as amended (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth herein and in the Stock Option Agreement, the Plan and the Notice of Exercise, all of which are included herewith and incorporated herein in their entirety.

Acadia Pharmaceuticals Inc – October 28, 2015 Srdjan “Serge” Stankovic (February 29th, 2016)
Acadia Pharmaceuticals Inc – REGISTRATION RIGHTS AGREEMENT (January 7th, 2016)

This Registration Rights Agreement (this “Agreement”) is made as of January 6, 2016, by and between ACADIA Pharmaceuticals Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.

Acadia Pharmaceuticals Inc – 10,344,827 Shares ACADIA PHARMACEUTICALS INC. UNDERWRITING AGREEMENT (January 7th, 2016)
Acadia Pharmaceuticals Inc – ACADIA Pharmaceuticals Inc. Management Severance Benefit Plan (December 15th, 2015)
Acadia Pharmaceuticals Inc – Amended and Restated Change in Control Severance Benefit Plan (December 15th, 2015)
Acadia Pharmaceuticals Inc – Master Manufacturing Services Agreement August 3, 2015 (November 5th, 2015)

THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each Party), and intending to be legally bound the Parties agree as follows:

Acadia Pharmaceuticals Inc – Contact: (November 5th, 2015)
Acadia Pharmaceuticals Inc – Co-operation Agreement (November 5th, 2015)

Whereas, BPE sells and markets pharmaceutical products manufactured by it and its Affiliates (as defined below), e.g. BASF Pharma (Saint-Vulbas) SAS (“BPSV”), BASF PharmaChemikalien GmbH & Co. KG (“BPCG”) as well as BASF SE in Germany (“BASF”).

Acadia Pharmaceuticals Inc – EMPLOYMENT AGREEMENT (September 3rd, 2015)

This Amended and Restated Executive Employment Agreement (the “Agreement”) is made and entered into effective as of September 1, 2015 (the “Effective Date”) by and between ACADIA Pharmaceuticals Inc., a Delaware Corporation (the “Company”), and Stephen R. Davis (“Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties”, and individually referred to each as a “Party”.

Acadia Pharmaceuticals Inc – Contacts: ACADIA Pharmaceuticals Inc. Steve Davis, Interim Chief Executive Officer Lisa Barthelemy, Director of Investor Relations (August 6th, 2015)
Acadia Pharmaceuticals Inc – ACADIA PHARMACEUTICALS INC. 2010 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 12, 2010 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2010 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2013 APPROVED BY THE STOCKHOLDERS: JUNE 7, 2013 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2015 APPROVED BY THE STOCKHOLDERS: JUNE 15, 2015 (June 19th, 2015)